Entera Bio Ltd. (ENTX) Insider Trading

Last 12 months

Insiders bought $141k on the open market and sold nothing.

Net open-market

+$141k

8 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

5 / 0

executives and directors

Last open-market buy

Mar 2026

Mar 9, 2026

Get an email when ENTX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Mar 9	Geno J Germano Director	Bought	20,000	$1.30	$26k	100%	Form 4
Mar 5	Sean Ellis Director	Bought	10,000	$1.23	$12k	5.6%	Form 4
Feb 12	Steven D Rubin Director	Bought	5,000	$1.49	$7k	50%	Form 4
Feb 10	Haya Taitel Director	Bought	7,500	$1.48	$11k	New	Form 4
Feb 10	Geno J Germano Director	Bought	20,000	$1.49	$30k	New	Form 4
Feb 9	Steven D Rubin Director	Bought	10,000	$1.20	$12k	New	Form 4
Feb 9	Sean Ellis Director	Bought	18,000	$1.24	$22k	11%	Form 4
Dec 29, 2025	Miranda Jayne Toledano Chief Executive Officer	Bought	11,000	$1.81	$20k	2.6%	Form 4

Mar 9
Geno J Germano
Director · bought 20,000 at $1.30
$26k
100% of stake
Mar 5
Sean Ellis
Director · bought 10,000 at $1.23
$12k
5.6% of stake
Feb 12
Steven D Rubin
Director · bought 5,000 at $1.49
$7k
50% of stake
Feb 10
Haya Taitel
Director · bought 7,500 at $1.48
$11k
New position
Feb 10
Geno J Germano
Director · bought 20,000 at $1.49
$30k
New position
Feb 9
Steven D Rubin
Director · bought 10,000 at $1.20
$12k
New position
Feb 9
Sean Ellis
Director · bought 18,000 at $1.24
$22k
11% of stake
Dec 29, 2025
Miranda Jayne Toledano
Chief Executive Officer · bought 11,000 at $1.81
$20k
2.6% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ENTX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Biological Products, (No Diagnostic Substances)

ELOXEloxx Pharmaceuticals, Inc.

CMPXCompass Therapeutics Inc.

SABSSab Biotherapeutics Inc.

ARTVArtiva Biotherapeutics Inc.

GLUEMonte Rosa Therapeutics, Inc.

ALGSAligos Therapeutics Inc.

SRRKScholar Rock Holding Corporation

ALECAlector Inc.

Spot a number that looks wrong? Check it in ENTX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ENTX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.